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ABSTRACT
RUNX2, a key transcription factor for osteoblast differentiation, is regulated by ERK1/2 and p38 MAP kinase-mediated phosphorylation.
However, the specific contribution of each kinase to RUNX2-dependent transcription is not known. Here we investigate ERK and p38
regulation of RUNX2 using a unique P-RUNX2-specific antibody. Both MAP kinases stimulated RUNX2 Ser319 phosphorylation and
transcriptional activity. However, a clear preference for ERK1 versus p38a/bwas found when the ability of these MAPKs to phosphorylate
and activate RUNX2 was compared. Similarly, ERK1 preferentially bound to a consensus MAPK binding site on RUNX2 that was essential
for the activity of either kinase. To assess the relative contribution of ERK1/2 and p38 to osteoblast gene expression, MC3T3-E1
preosteoblast cells were grown in control or ascorbic acid (AA)-containing medium BMP2/7. AA-induced gene expression, which
requires collagen matrix synthesis, was associated with parallel increases in P-ERK and RUNX2-S319-P in the absence of any changes in
P-p38. This response was blocked by ERK, but not p38, inhibition. Significantly, in the presence of AA, BMP2/7 synergistically stimulated
RUNX2 S319 phosphorylation and transcriptional activity without affecting total RUNX2 and this response was totally dependent on ERK/
MAPK activity. In contrast, although p38 inhibition partially blocked BMP-dependent transcription, it did not affect RUNX2 S319
phosphorylation, suggesting the involvement of other phosphorylation sites and/or transcription factors in this response. Based on this
work, we conclude that extracellular matrix and BMP regulation of RUNX2 phosphorylation and transcriptional activity in osteoblasts is
predominantly mediated by ERK rather than p38 MAPKs.  2012 American Society for Bone and Mineral Research.
KEY WORDS: OSTEOBLAST; TRANSCRIPTION; PHOSPHORYLATION; MAPK; RUNX2
Introduction
Several transcription factors including DLX5/6, TWIST1/2,ATF4, RUNX2, and Osterix control bone cell lineages.(1–6) Of
these, RUNX2 and Osterix (OSX) have the most selective roles
in osteogenesis. Deletion of either factor in mice results in
severe defects in skeletal development. Runx2-null mice have
a cartilaginous skeleton that contains no bone mineral or
hypertrophic cartilage. In contrast, Osx, which is genetically
downstream of Runx2, has a more selective role in osteoblast
formation and skeletal mineralization.(3–5) In addition to its
essential role in bone development, Runx2 is necessary
throughout life to promote the differentiation of new osteoblasts
during bone remodeling.(2)
Consistent with its fundamental role in bone formation,
RUNX2 is tightly regulated. In addition to transcriptional control
by factors such as bone morphogenetic proteins,(7) RUNX2
activity is regulated both by its interaction with a number of
accessory nuclear factors and by posttranslational modifications,
including phosphorylation. We have been particularly interested
in this latter control mechanism and showed that ERK1/2 MAPK-
dependent phosphorylation of RUNX2 is critical for osteoblast-
specific gene expression and differentiation.(8,9) This pathway
mediates the response of bone cells to a variety of signals
including hormone/growth factor stimulation,(10,11) extracellular
matrix binding/matrix tension,(12–15) and mechanical load-
ing.(16,17) ERK1/2 phosphorylates four serine residues on RUNX2
(S43, S301, S319, and S510, using the amino acid residue
numbering for murine Type II RUNX2 isoform having N-terminal
sequence MASN).(18) Of these, S301 and S319 are required for
transcriptional activity because S to A mutations at these sites
greatly reduces the ability of RUNX2 to stimulate osteoblast gene
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expression. ERK1 and ERK2 directly bind to RUNX2 via a
consensus MAPK docking or ‘‘D’’ site in its C-terminal region
distal to the runt domain. This RUNX2–ERK interaction also
occurs on the chromatin of target genes in vivo and is necessary
for activation of RUNX2 by the ERK/MAPK pathway.(18,19)
Further evidence for the crucial role of ERK/MAPK signaling
in osteogenesis is provided by transgenic mouse studies.
Specifically, overexpression of constitutively active or domi-
nant-negative forms of the MAPK intermediate, MEK1, in
osteoblasts, respectively stimulated or inhibited bone develop-
ment, as well as RUNX2 phosphorylation.(20) Effects of MAPK on
development are at least in part mediated by RUNX2, because
the cleidocranial dysplasia phenotype of Runx2 heterozygous
null mice can be partially rescued by crossing these animals with
mice expressing constitutively active MEK1. In related studies,
Prx1-cre-mediated inactivation of Erk2 in osteochondroprogeni-
tor cells of developing Erk1-null mice was shown to block
osteoblast differentiation leading to ectopic cartilage formation
in regions of the perichondrium that normally form bone.
Furthermore, increased ERK/MAPK signaling in the same cell
population increased osteoblast differentiation and inhibited
chondrogenesis.(21)
Recent evidence also supports a role for the p38 MAPK
pathway in osteoblast differentiation as part of downstream
signaling from the transforming growth factor (TGF)-b/bone
morphogenetic protein (BMP)-responsive kinase, TAK1.(22)
Specifically, conditional deletion of TAK1 in osteoblasts using
Osx-Cre results in a severe skeletal phenotype that includes low
cortical and trabecular bone mass, clavicular hypoplasia, and
delayed fontanelle fusion. Although TAK1 stimulates ERK,
JNK, and p38 MAP kinases,(23) its actions in osteoblasts were
attributed to activation of p38 and subsequent RUNX2
phosphorylation. Consistent with this model, mice harboring
deletions in the p38 MAPK intermediates, Mkk3, Mkk6, p38a, or
p38b, all had decreased bone mass.(22) Three p38 phosphoryla-
tion sites on RUNX2 were identified (S31, S254, and S319)
and their combined mutation was shown to reduce RUNX2
transcriptional activity.
Interestingly, one of the p38 phosphorylation sites on RUNX2
(S319) had previously been identified as a substrate for ERK1/
2(18). This finding raises the intriguing possibility that ERK and
p38 MAPKs have overlapping functional roles in the control of
osteoblast gene expression and differentiation. In the present
study, we explore this concept as well as compare the relative
importance of these two MAPKs in directly controlling RUNX2
phosphorylation and transcriptional activity.
Experimental Procedures
Reagents
The reagents used in this study were obtained from the following
sources: tissue culture medium and fetal bovine serum from
Hyclone (Logan, UT, USA), and Invitrogen (Carlsbad, CA, USA);
recombinant BMP2/7 from R&D (Minneapolis, MN); ITS, U0126,
and SB203580 from Sigma (St. Louis, MO, USA); phospho-ERK,
total-ERK, phospho-p38, total p38, and total-SMAD1/5/8 anti-
bodies from Cell Signaling (Danvers, MA, USA); phospho-SMAD1/
5/8 antibody from Santa Cruz (Santa Cruz, CA, USA). and RUNX2
antibody from MBL (Japan).
Generation of a phospho-RUNX2-specific antibody
Convance (Princeton, NJ, USA) using the following peptide as
immunogen, produced an antibody that specifically detects
RUNX2 phosphorylated at S319: YPSYLSQIMTS(P)PSIHSTTPL. The
peptide was conjugated to Keyhole limpet hemocyanin (KLH)
and injected into rabbits at 4-week intervals for a total of three
injections. After 12 weeks, the serum was harvested and affinity
purified using a column containing nonphosphorylated peptide
to remove antibody against total RUNX2 followed by a second
affinity step using a phosphopeptide-containing column.
DNA constructs and viral expression vectors
The 6OSE2-luc RUNX2 reporter and pCMV-RUNX2 expression
vector were previously described.(24,25) Constitutively active
MEK1 (Meksp) and dominant negative MEK1 (MEKDN and kinase
dead ERK1 (ERK1DN) expression vectors were obtained from
Dr Kun Liang Guan (Univ. of California San Diego).(26,27)
Constitutively active MKK6, dominant negative MKK6, and
dominant negative p38 expression vectors were described
previously.(28) Plasmids expressing constitutively active MEK1,
wild-type RUNX2, S301A,S319A mutant RUNX2, and RUNX2
containing a deletion of the MAPK-binding D site (D200–215)
were developed in the project laboratory.(18,29)
Cell cultures and animal studies
COS7 cells were obtained from the American Type Culture
Collection (Rockville, MD, USA) and maintained in Delbecco’s
Modified Eagle Medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% antibiotics. MC3T3-E1 clone 42 cells (MC42 cells),
which contain stably integrated copies of 1.3 kilobytes (kb)
murine mOG2 promoter driving luciferase, were previous
developed in this laboratory.(30) To induce differentiation, cells
were plated at a density of 5 104 cells/cm2 and cultured in
a-Minimum Essential Medium (MEM), 10% FBS containing
50mg/mL ascorbic acid (AA) for up to 14 days. Primary calvarial
cells were isolated from newborn transgenic mice previously
developed in this laboratory that use a 0.6 kb mOG2 promoter to
drive dominant negative (TgMekdn) or constitutively active
(TgMeksp) MEK1 in osteoblasts(20) and differentiation/minerali-
zation was induced by growth in a-MEM, 10% FBS, 50mg/mL AA
and 3mM inorganic phosphate for 14 days. For calvarial bone
organ cultures, calvaria were isolated from E18.5 C57BL6 mice
and cultured in a-MEM with 1% ITS, 50mg/mL AA, and 3mM
inorganic phosphate for up to 6 days. Medium was changed
daily. Mineral was visualized using the either Alizarin Red or von
Kossa staining as indicated. All studies withmice were performed
in compliance with the University of Michigan Committee for the
Use and Care of Animals.
Transfections
COS7 cells were plate at a density of 5 104 cells/cm2 and
transfected with the indicated plasmids using Lipofectamine
(Invitrogen). For each dish, 0.05mg of pRL-SV40 containing a
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cDNA for renilla reformis luciferase was used as a control for
transfection efficiency. Cells were harvested 48 hours after
transfection and assayed using a dual luciferase kit (Promega,
Madison, WI, USA) with a Monolight 2010 luminometer
(Pharmingen, San Diego, CA, USA).
Immunofluorescence microcopy
MC3T3-E1 clone 42 and transfected COS7 cells were grown on
glass cover slips, fixed with 4% formaldehyde, and incubated
overnight at 48C with primary antibodies to total and
phosphorylated RUNX2 (1:500 dilution). Alexa Fluor 488
conjugated donkey antimouse and Alexa Fluor 555 conjugated
donkey antirabbit (Invitrogen) antibodies were used to visualize
the localization of total and S319-P RUNX2. Fluorescence
detection was accomplished using Nikon Eclipse 50i microscope
and imaging system.
Western blots and immunoprecipitation
For Western blots, cell extracts were prepared by directly
dissolving cells in 2 SDS sample buffer (Invitrogen). For
immunoprecipitations, cells were harvested in immunoprecipi-
tation (IP) buffer containing 20mM Tris, pH7.6, 500mM NaCl,
0.25% NP40, 5mM NaF, 1mM ethylene glycol tetraacetic acid
(EGTA), 1% proteinase inhibitor, and 1% phosphatase inhibitor
(Sigma). The indicated antibodies were added and incubated
overnight at 48C with gentle rocking. Immunocomplexes were
then collected by protein A/G agarose beads and released by
boiling with SDS sample buffer. Samples were fractionated by
SDS-PAGE using 6% to 20% gradient gels (Invitrogen). After a
transfer to nitrocellulose membranes, samples were incubated
with the indicated antibody (1:500 dilution) overnight at 48C.
Sheep antimouse or donkey antirabbit second antibody
conjugated with horseradish peroxidase (GE Healthcare, UK)
was used at a 1:10,000 dilution. Horseradish peroxidase activity
was detected by ECL (Amersham, Arlington Heights, IL, USA).
Statistical analysis
All statistical analyses were performed using SPSS 16.0 Software.
Unless indicated otherwise, each reported value is the
mean SD of triplicate independent samples. Statistical signifi-
cance was assessed using a one-way analysis of variance.
Results
Development of a phospho-RUNX2-specific antibody
The ERK/MAPK pathway plays an important role in the control of
osteoblast gene expression and differentiation by stimulating
RUNX2 phosphorylation.(8,14,18,20) S301 and S319 are of particular
importance in that their mutation to alanine greatly reduces the
ability of RUNX2 to stimulate osteoblast gene expression. P38
MAPK can also phosphorylate RUNX2 in response to TGF-b/BMP
activation of TAK1.(22) Interestingly, one of the ERK1/2 sites we
described, S319, is also phosphorylated by p38a. Because it is a
substrate for both kinases, we considered it likely that S319-P
would be indicative of overall RUNX2 activation state and a good
candidate for antibody production. The peptide containing
S319-PO4, which was used to immunize rabbits, is conserved
across mouse, rat, and human species. A site homologous to
S319 is also present in RUNX1 (AML1), although the flanking
sequence is different from RUNX2 (Fig. 1A). A polyclonal antibody
was generated to the RUNX2 phosphopeptide and affinity
purified using positive and negative selection (see Experimental
Procedures). As shown in Figure 1B, the P-RUNX2 antibody
selectively detects wild-type RUNX2, but not RUNX2 containing
S301A,S319A mutations. Furthermore, staining intensity in-
creased when COS7 cells were transfected with a constitutively
active form of MEK1 (Meksp). In contrast, total RUNX2, measured
with a commercially available antibody, remained unchanged
under these conditions. The phospho-RUNX2 antibody did not
crossreact with phosphorylated RUNX1 (result not shown).
The S-319-P antibody also selectively detects phospho-Runx2
in intact cells when examined by immunofluorescence micro-
scopy (Fig. 1C). Antibody clearly stains phosphorylated RUNX2 in
COS7 cells transfected with wild-type RUNX2, but gave no signal
with the S301A,S319A mutant. Staining for both wild-type and
mutant RUNX2 revealed a predominantly nuclear localization.
In summary, the RUNX2-S319-P antibody is able to discriminate
between RUNX2 in different phosphorylation states and should
be a powerful tool for monitoring activation of this transcription
factor.
RUNX2 is phosphorylated and activated by both
ERK1/2 and p38 MAP kinases; preferential activation
by ERK1/2
To compare the ability of ERK1/2 and p38 to stimulate RUNX2
phosphorylation and transcriptional activity, COS7 cells were
transfected with a RUNX2 expression vector and increasing
amounts (0.05–1.0mg plasmid DNA) of constitutively active
forms of MEK1 (Meksp; activates ERK1/2) or MKK6 (Mkk6sp;
activates p38). RUNX2-dependent transcriptional activity was
measured using a 6OSE2-luc-reporter gene (contains six copies
of the RUNX2-specific enhancer, OSE2, driving luciferase; Fig. 2,
top) and changes in RUNX2 phosphorylation and MAP kinase
activation were measured on Western blots (Fig. 2, bottom).
Meksp or Mkk6sp each dose-dependently increased P-ERK or P-
p38, respectively, and stimulated RUNX2-S319 phosphorylation
and transcriptional activity. Maximum stimulation by each MAP
kinase kinase was achieved with 0.5mg plasmid DNA, with no
further increases noted at higher concentrations. This indicates
that Meksp or Mkk6sp plasmids were in excess relative to their
respective MAPK substrate (ERK1/2 or p38) at or above this level.
However, large differences were observed in the magnitude of
responses. Saturating amounts of Meksp stimulated transcrip-
tional activity approximately 12-fold and strongly induced
RUNX2 phosphorylation while Mkk6sp only stimulated transcrip-
tion 2.9-fold and induced a barely detectable increase in RUNX2-
P. Similarly, both kinases increased levels of nuclear RUNX2-S319-
P in osteoblasts as measured by immunofluorescence, but
the amount of the stimulation was much greater in the
Meksp-treated group.
To exclude the possibility that endogenous levels of ERK and
p38 were limiting the magnitude of Meksp and Mkk6sp
stimulation in the experiment shown in Figure 2, a second
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study was carried out where cells were transfected with
increasing amounts of ERK1, p38a, or p38b in the presence of
excess Meksp or Mkk6sp plasmids, respectively (Fig. 3A, B). The
amount of Meksp or Mkk6sp expression plasmid used (0.5mg
DNA each) was based on results in Figure 2 that showedmaximal
stimulation of ERK or p38 phosphorylation at or above this
amount of plasmid. Studies focused on p38a and b because
these isoforms were previously reported to phosphorylate
RUNX2.(22) In the absence of upstream activation, ERK1 or p38a/
b overexpression minimally affected RUNX2-dependent tran-
scriptional activity (Fig. 3A). However, a clear dose-dependence
was found for all three MAPKs when cells were also transfected
with excess Meksp or Mkk6sp. Peak activation of RUNX2
phosphorylation and transcriptional activity was found with
0.5mg of each MAPK expression vector with a partial drop found
with 0.75mg. However, large differences were found in the
magnitude of 6OSE2-luc reporter activation with ERK1 having
the highest activity (Meksp/control¼ 16) followed by p38b
(Mkk6sp/control¼ 6.9) and p38a (MKK6/control¼ 4.3). Large
differences in peak luciferase activities were also found.
Normalized luciferase activities were as follows: ERK1, 6.0;
p38b, 1.5; p38a, 0.65 (ratios: ERK1:p38b:p38a¼ 9.1:2.3:1.0).
Similar differences were found in the ability of each MAPK to
stimulate RUNX2 phosphorylation with RUNX2 being more
extensively phosphorylated by the ERK1/Meksp combination
than by p38b/Mkk6sp or p38a/Mkk6sp (Fig. 3B).
ERK1 and p38b share and compete for a common
docking site on RUNX2
To better compare ERK1/Meksp and p38b/Mkk6sp stimulation
of RUNX2 activity, COS7 cells were transfected with optimal
amounts of each expression vector in the combinations
indicated. Results are presented both in terms of absolute
Fig. 1. Characterization of RUNX2-S319-PO4-specific antibody. (A) Sequence alignment of mouse, rat, and human RUNX2 and human RUNX1.
The conserved phosphoserine site is indicated (). (B) P-RUNX2 antibody specifically detects RUNX2-S319 phosphorylation. COS7 cells were transfected
with wild-type (WT) or S301A,S319A mutant RUNX2 (SA) expression vectors in the presence or absence of a constitutively active MEK1 (SP).
Western blots were probed with P-RUNX2 or total RUNX2 antibody. (C) Immunofluorescence detection of P-RUNX2. COS7 cells were transfected
with wild-type (WT) or S301A,S319A mutant RUNX2 expression vectors and stained with the indicated antibodies. Red, phospho-RUNX2; green, total
RUNX2. Bar¼ 20mm.
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activity and fold-stimulation relative to control cells transfected
with 6OSE2-luc and RUNX2 only (Fig. 3C). Because of the
increased availability of endogenous ERK1 in COS7 cells,
overexpression of Meksp alone induced a 12-fold stimulation
of luciferase activity. This was further increased to 16-fold with
ERK1 transfection. In contrast, MKK6 increased activity 2.9-fold,
and this was further increased to only 6.9-fold with p38b.
Surprisingly, when optimal amounts of ERK1/Meksp and p38b/
Mkk6sp were combined, neither an additive nor synergistic
stimulation of transcriptional activity or RUNX2 phosphorylation
was observed. Instead, RUNX2 phosphorylation and activity
were actually lower than the ERK1/Meksp group (p< 0.01).
Competition between ERK1 and p38b for a common docking
site on RUNX2 is a possible explanation for this result. Our
previous work showed that RUNX2 contains a conserved ERK1/2
docking motif or ‘‘D’’ site between amino acid residues 200 and
215.(18) Because this motif is also recognized by JNK/SAPKs and
p38 MAPKs when present in other transcription factors such
as SAP-1/2, ATF-2, or ELK-1,(31,32) it is possible that it could also
serve as binding site for p38. In fact, p38 was previously shown
to bind RUNX2 in coimmunoprecipitation assays, although the
actual binding region was not defined.(22) In the study shown in
Figure 4A, coimmunoprecipitation assays were used to demon-
strate competition between P-ERK1/2 and P-p38 for binding
sites on RUNX2 under conditions where either ERK or p38 was
activated by increasing amounts of Meksp or Mkk6sp. For all
groups, COS7 cells were transfected with FLAG-tagged RUNX2
and optimal amounts of either Mkk6sp or Meksp. M2 antibody
Fig. 2. ERK and p38 MAP kinase stimulation of RUNX2 phosphorylation and transcriptional activity. (A) MEK1 and MKK6 dose–response. COS7 cells were
transfected with wild-type RUNX2 expression vector, 6OSE2-luc reporter, and increasing amounts of either constitutively active MEK1 (Meksp) or MKK6
(Mkk6sp) expression vectors (0.05, 0.1, 0.25, 0.5, 0.75, 1.0mg/dish) (upper panel). Firefly luciferase activities were normalized to renilla pyriformis luciferase
plasmid. Results are presented as normalized luciferase activity (F/r) and fold-stimulation relative to a LacZ control transfection. RUNX2-S319-P, P-ERK1/2,
and P-p38 were detected by Western blotting using the indicated antibodies (lower panel). (B) Immunofluorescence detection of endogenous RUNX2
phosphorylation in MC3T3E1 preosteoblast cells. MC3T3-E1 clone 4 cells were transfected with control (LacZ), Meksp, or Mkk6sp expression vectors and
stained with P-RUNX2 antibody as indicated. Bar¼ 20mm.
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(anti-FLAG) was then used to immunoprecipitate total RUNX2
and associated P-ERK or P-p38. As cells were transfected with
increasing amounts of Meksp in the presence of optimal Mkk6sp,
a concomitant increase in RUNX2-associated P-ERK1/2 was
observed while the amount of bound P-p38 decreased. Similarly,
when cells were transfected with increasing Mkk6sp, bound
P-p38 increased at the expense of P-ERK.
To determine whether competition between ERK and p38
affected RUNX2 transcriptional activity and phosphorylation,
COS7 cells were transfected with optimal amounts (based on
results shown in Fig. 3) of either Meksp/ERK1 (Fig. 4B, D) or
Mkk6sp/p38b (Fig. 4C, E) expression plasmids and increasing
amounts of dominant-negative ERK1 or p38. Cells were then
assayed for RUNX2-dependent transcriptional activity (Fig. 4B, C)
Fig. 3. Preferential stimulation of RUNX2 phosphorylation and transcriptional activity by ERK1 versus p38a and p38b. COS7 cells were transfected with
wild-type RUNX2 expression vector, 6OSE2-luc reporter, and the indicated amounts of ERK1, p38a, or p38b with or without excess Meksp or Mkk6sp
(0.5mg each). (A) RUNX2 transcriptional activity. Results are expressed in terms as normalized luciferase activity and fold-stimulation (Meksp/LacZ or
Mkk6sp/LacZ). (B) RUNX2, ERK, and p38 phosphorylation. (C) Combined activities of ERK1/Meksp and p38b/Mkk6sp. COS7 cells were transfected with
optimal amounts of ERK1/Meksp or p38b/Mkk6sp combinations (0.5mg of each plasmid) as determined in (A). RUNX2-dependent transcriptional activity
(upper panel) and phosphorylation of RUNX2, ERK1/2, and p38 (lower panel) are shown. Note that ERK1/Meksp plus p38b/Mkk6sp group has less activity
than ERK1/Meksp alone. (M) Statistically significant differences are indicated, p< 0.01.
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Fig. 4. ERK and p38 compete for a common docking site on RUNX2. (A) Coimmunoprecipitation studies. COS7 cells were transfected with a FLAG-tagged
RUNX2 expression vector and the indictated amounts of Mkk6sp or Meksp vectors. Nuclear extracts were immunoprecipitated with M2 (anti-FLAG)
antibody and blots probed with anti-RUNX2, anti-P-ERK, and anti-P-p38 antibodies as indicated. Note the reciprocal relationship between bound P-ERK
and P-p38. (B–E) Dominant-negative ERK1 or p38b inhibit both ERK and p38 stimulation of RUNX2 transcriptional activity. COS7 cells were transfected with
RUNX2 expression vector, 6OSE2-Luc, and optimal amounts (0.5mg DNA each) of Meksp/ERK1 (B,D) or Mkk6sp/p38b (C,E) and the indicated amounts of
ERK1(DN) or p38b(DN). Samples were then assayed for luciferase activity (B,C) and Western blots were probed with antibodies against total or P-RUNX2,
total ERK1/2 and total p38 (D,E). The ERK blot detected both endogenous (lower arrow) and transfected ERK/ERK(DN) (upper arrow), while the p38 blot
detected endogenous p38 (lower arrow) and transfected p38/p38(DN) (upper arrow). ( F) Dominant-negative MKK6 (Mkk6dn) stimulates RUNX2
transcriptional activity and phosphorylation. COS7 cells were transfected with a RUNX2 expression vector and 6OSE2-Luc with the indicated amounts
of Mkk6dn vector. Shown are normalized luciferase activity (upper panel) and RUNX2, ERK, and p38 phosphorylation (lower panel). (G) Ability of ERK and
p38 to stimulate RUNX2-dependent transcription requires a MAPK docking site on RUNX2. COS7 cells were transfected with wild-type RUNX2 or RUNX2
containing a MAPK docking site deletion (D-site), 6OSE2-luc reporterMeksp, Mkk6sp, or both expression vectors. Cells were assayed for luciferase
activity (upper panel) or total/phosphorylated RUNX2 (lower panel). (M) Statistically significant difference is indicated, p< 0.01.
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and levels of RUNX2-S319-P, total ERK, and total p38 protein
(Western blots; Fig. 4D, E). Because they were epitope-tagged,
transfected ERK1, ERK1(DN), p38b, and p38b(DN) could be
distinguished from endogenous kinases by their reduced
electrophoretic mobility (see arrows, Fig. 4D, E, bottom 2 rows).
For example, in the row probed for total ERK in Panel D, the
upper band in lane 1 reflects levels of wild-type ERK1 transfected
into cells. Because transfected wild-type and mutant ERK have
the same mobility, the increased intensity of this band in the
lanes 2–5 reflects increasing amounts of transfected ERK(DN).
Similarly, the upper band in lanes 6–10 of the p38 row measures
p38(DN). The same analysis applies to the results shown in Panel
E, except in this case all cells were transfected with p38b instead
of ERK1, so the ERK(DN) band is clearly visible (lanes 1–5),
whereas p38(DN) is only distinguished from transfected wild-
type p38b by the increased intensity of the total p38 band in
samples transfected with increasing amounts p38(DN) (lanes 6–
10). As expected, ERK1(DN) strongly inhibited ERK1/Meksp-
stimulated RUNX2 activity and phosphorylation. Under this
condition, p38(DN) was only weakly inhibitory. On the other
hand, when Mkk6sp/p38b activity was examined, ERK1(DN) and
p38(DN) were both strongly inhibitory although ERK1(DN) was
still somewhat more active. These are the results that would be
expected if ERK1 had a higher affinity for the RUNX2 D site than
p38.
Similarly, in the experiment shown in panel F, COS7 cells were
transfected with increasing amounts of dominant-negative
MKK6 (MKK6dn). This strongly inhibited basal P-p38 levels
while dramatically increasing P-ERK, RUNX2 phosphorylation,
and transcriptional activity. Again, this would be the result
expected if suppression of the less active p38 were allowing
more RUNX2 docking sites to be available for P-ERK, leading to
increased RUNX2 phosphorylation and transcriptional activity.
A final experiment in this section examined the requirement
for an intact RUNX2 D site for ERK and p38-mediated RUNX2
phosphorylation/transcriptional activity (Fig. 4G). COS7 cells
were transfected with wild-type RUNX2 or RUNX2 containing a D
site deletion (D200–215) and stimulated with Meksp, Mkk6sp,
or both kinases. With wild-type RUNX2, Meksp preferentially
stimulated transcriptional activity and RUNX2-S319-P versus
Mkk6sp, and, as expected, the Meksp/Mkk6sp combination was
less active than Meksp alone. In contrast, neither kinase had any
activity with the D site deletion mutant.
Effect of ERK and p38 MAPK inhibitors; reciprocal
activation of ERK1/2 and p38 pathways
Pharmacological inhibitors were used to further explore the
role of ERK and p38 MAPKs in bone cells. Studies shown in
Figure 5 examined effects of inhibitors on transfected COS7 cells,
MC3T3-E1 clone 42 preosteoblast cells, and calvarial bone organ
cultures. In all cases, cultures were titrated with the indicated
inhibitor to give maximal suppression of p-ERK1/2 or P-p38,
respectively (result not shown). Inhibitors were added 16 hours
before harvest to minimize the nonspecific toxic effects
associated with prolonged exposures.(14) In COS7 cells, the
ERK/MAPK inhibitor, U0126, blocked RUNX2 activity (p< 0.01)
and inhibited ERK and RUNX2 S319 phosphorylation. In contrast,
SB203580 (SB), a p38/MAPK inhibitor, while clearly blocking p38
phosphorylation, actually increased P-ERK, RUNX2 transcriptional
activity, and phosphorylation (Fig. 5A). This may explain why
there was no decrease in overall RUNX2-dependent transcription
under this condition. Addition of both inhibitors decreased
RUNX2 activity and phosphorylation below levels found with
U0126 alone, which suggests that p38/MAPK also contributed to
basal RUNX2 activity.
To assess the applicability of these findings to bone cells,
inhibitor effects were also examined in MC42 preosteoblast
cells (Fig. 5B) and calvarial organ cultures (Fig. 5C, D). MC42 cells,
which contain stably integrated copies of a 1.3- kb mOG2-luc
reporter,(30) were grown in AA-containing medium for 6 days to
induce differentiation and mOG2-luc activity. In these cells,
mOG2-luc activity is proportional to endogenous osteoblast
gene expression and differentiation.(30) Cells were then treated
with U0126 and/or SB203580 for 16 hours immediately before
harvest. As previously reported,(14) U0126 dramatically inhibited
mOG2-luc activity. This inhibitor also blocked ERK and endoge-
nous RUNX2 phosphorylation while increasing P-p38. In contrast,
SB actually mildly stimulated ERK and RUNX2 phosphorylation
and transcription. However, when it was combined with
U0126, SB further decreased mOG2-luc activity and RUNX2
phosphorylation.
For calvarial organ cultures, bones were isolated from E18.5
mouse embryos and cultured for 5 days with AA and 2mM
inorganic phosphateU0126 or/and SB203580 (Fig. 5C, D).
Mineralization was measured using Alizarin red staining. During
the 5-day culture period, sutures went from a patent state
to nearly total fusion. U0126 or SB203580 each significantly
inhibited mineralization although the ERK inhibitor was
somewhat more active and an even greater inhibition was
observed when both compounds were used. Similar to cell
culture results, Western blot analysis of calvarial extracts showed
that U0126 reduced P-ERK and RUNX2 S319 phosphorylation
while mildly increasing P-p38. In contrast, P-p38 inhibition
had no obvious effect on RUNX2 phosphorylation and increased
P-ERK while combining U0126 and SB blocked both pathways
and reduced RUNX2 phosphorylation below levels found with
U0126 alone.
A final example of this reciprocal regulation is shown in
Figure 6. In this study, calvarial osteoblasts were isolated from
previously generated transgenic mice in which a 0.6-kb mOG2
promoter was used to drive dominant negative (TgMekdn) or
constitutively active (TgMeksp) MEK1 in osteoblasts (Fig. 6A, B).
In these animals, Mekdn delayed embryonic bone development
while Meksp accelerated osteogenesis.(20) Cells were prepared
from newborn wild-type mice and cultured under differentiating
conditions for 14 days. As previously reported, TgMeksp cells
exhibited increased mineralization relative to wild-type while
TgMekdn cells were under mineralized.(20) Western blot analysis
(Fig. 6B) revealed that endogenous ERK and RUNX2-S319
phosphorylation was decreased in TgMekdn cells while P-p38
was increased. In contrast, ERK and RUNX2 phosphorylation were
increased and P-p38 was inhibited in TgMeksp cells. U0126
inhibited ERK and RUNX2 phosphorylation in WT and TgMekdn
groups, but not in cells from TgMeksp mice that were resistant
because of the constitutively active Mek1 transgene. U0126 also
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Fig. 5. Reciprocal relationship between ERK1/2 and p38 MAPK activities: effect of ERK1/2 and p38 MAPK inhibitors on RUNX2 transcriptional activity and
phosphorylation. (A) COS7 cells. Cells were transfected with a wild-type RUNX2 expression vector and 6OSE2-Luc reporter and grown for 48 hours. Sixteen
hours before harvest, cells were treated with 20mM U0126 (ERK/MAPK inhibitor), 20mM SB203580 (SB, a p38/MAPK inhibitor), or both compounds. Cells
were assayed for luciferase activity (upper panel) and phosphorylation of RUNX2, ERK1/2, and p38 (lower panel). (B) MC3T3-E1 clone 42 preosteoblasts.
These cells contain stably transfected copies of a 1.3-kb murine osteocalcin gene 2 (mOG2) promoter driving a firefly luciferase reporter. Cells
were cultured using differentiation conditions described in Experimental Procedures and treated with U0126 or SB203580 for 16 hours before harvest.
Upper panel: mOG2 promoter activity. Lower panel: RUNX2, ERK, and p38 phosphorylation. (C,D) Calvarial organ cultures. Calvaria were isolated from
E18.5 day mouse embryos and cultured for 5 days as described in Experimental ProceduresU0126 or/and SB203580. Cultures were stained for
mineral using Alizarin red (upper panel). Lower panel: phosphorylation of RUNX2, ERK, and p38. Statistically significant differences are indicated:
Mp< 0.05; MMp< 0.01.
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further increased the already high levels of phosphorylated p38
in TgMekdn cells. Inhibition of p38 lowered RUNX2 phosphory-
lation and mildly increased P-ERK in wild-type and TgMekdn
cells, but led to a dramatic increase in P-ERK, and RUNX2
phosphorylation in TgMeksp cells.
Taken together, these studies show that there is a reciprocal
relationship between ERK1/2 and p38MAPK pathways; inhibition
of one leads to activation of the other. Furthermore, because of
competition between the two kinases for the RUNX2 docking
site, inhibition of p38 actually makes RUNX2 more available for
ERK phosphorylation and activation.
Role of ERK1/2 and p38 signaling in extracellular matrix
and BMP-induced osteoblast differentiation
Extracellular matrix (ECM) and BMP signals synergistically
interact to stimulate osteoblast gene expression and
differentiation.(14) The basis for this interaction is not known.
However, binding of type I collagen to a2b1 integrins or the
discoidin receptor type 2 (DDR2) stimulates ERK/MAPK, RUNX2
phosphorylation, and gene expression.(13,33,34) whereas BMP
activation of type I and II BMP receptors activates receptor SMAD
proteins as well as TAK1. Because this kinase also stimulates ERK
and p38 MAP kinases,(22,23) the potential exists for extracellular
matrix and BMP signals to interact at the level of kinase activation
of RUNX2. To explore this possibility, we examined MAP kinase
activation and RUNX2 S319 phosphorylation inMC42 cells during
AA-induced differentiation in the presence or absence of BMP2/7
heterodimer (Fig. 7). Previous worked showed that actions of
this vitamin on differentiation require collagen synthesis and
binding to a2b1 integrins.(13,35)
To first evaluate the AA-induced component of kinase
signaling, cells were grown in control or AA-containing medium
for 3, 7, 10, and 14 days and gene expression (1.3 kb mOG2-luc
activity), kinase activation and RUNX2 phosphorylation were
measured (Fig. 7A, B). As previously reported, AA strongly
induced osteocalcin promoter activity.(13,30) Furthermore, time-
dependent increases were found in ERK1/2 and RUNX2 S319
phosphorylation only in cells grown in AA-containing medium.
In contrast, little to no change was found in the level of p38
phosphorylation. This suggests that AA-induced differentiation is
mainly associated with ERK/MAPK activation/phosphorylation
of RUNX2.
Studies shown in Figure 7C and D examined combined effects
of AA and BMP2/7 on transcriptional activity, kinase signaling,
and RUNX2-S319 phosphorylation. As previously reported,(14)
BMP treatment dose-dependently increased mOG2-luc activity
and this response was synergistically stimulated when BMP2/7
was added in the presence of AA (Fig. 7C). In the absence of AA,
BMP2/7 also weakly stimulated RUNX2, ERK, p38, and Smad 1/5/8
phosphorylation without affecting total RUNX levels (Fig. 7D).
P-RUNX2 and P-ERK levels were reduced by U0126 while p38
inhibition did not affect promoter activity or Smad phosphory-
lation and slightly increased RUNX2 and ERK phosphorylation.
Consistent with results shown in Figure 5B, treatment with AA
alone increased promoter activity, RUNX2, and ERK phosphory-
lation, and all these responses were sensitive to ERK, but not p38
inhibition. Significantly, in the presence of AA, BMP2/7 dramatic
stimulated mOG2-luc activity, RUNX2, ERK, and p38 phosphory-
lation and modestly increased Smad1/5/8 phosphorylation
without affecting total RUNX2. ERK/MAPK inhibition reduced
promoter activity and ERK/RUNX2 phosphorylation to basal
levels without affecting SMAD phosphorylation. Under these
conditions, p38 inhibition also partially inhibited mOG2-luc
activity, but surprisingly, did not affect RUNX2 phosphorylation.
Two important conclusions may be drawn from these studies:
first, the BMP pathway can stimulate RUNX2 S319 phosphoryla-
tion and transcriptional activity, particularly in the presence of
AA, and this stimulation is not associated with increased levels of
RUNX2. Second, although BMPs via TAK1 are know to activate
all three MAPKs, ERK1/2 is a major mediator of this response
in cultured osteoblasts with p38 having a minor role via a
mechanism unrelated to RUNX2 S319 phosphorylation.
Discussion
In this study, a variety of approaches were used to examine ERK1/
2 and p38 signaling in osteoblasts and relate kinase activities
to phosphorylation and activation of the RUNX2 transcription
factor. Although RUNX2 was a substrate for both kinases, it was
preferentially phosphorylated/activated by ERK1 relative to p38a
or b. Additional novel findings include the discovery that both
ERK and p38 MAPKs compete for a common docking site on
Fig. 6. Reciprocal relationship between ERK1/2 and p38 MAPK activities:
Transgenic modification of ERK/MAPK signaling alters osteoblast differ-
entiation, RUNX2 phosphorylation, ERK1/2, and p38 activities. Primary
calvaria cells were isolated from newborn wild-type mice (WT),
mice expressing dominant-negative (TgMekdn) or constitutively active
(TgMeksp) MEK1 in osteoblasts and differentiation was induced as
described in Experimental Procedures. Cells were grown for 14 days
and treated with U0126 or SB203580 16 hours before harvest as indicat-
ed. (A) Mineralization. Cells were stained according to the method of
von Kossa. (B) RUNX2, ERK, and p38 phosphorylation.
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RUNX2, the observation that these two kinase classes are
reciprocally regulated and the demonstration that RUNX2-S319
phosphorylation is strongly stimulated by BMP treatment,
particularly in the presence of ascorbic acid. Last, ERK and
p38 were shown to have separate but overlapping roles in
mediating the response of bone cells to AA and BMP signals.
Transgenic studies clearly established the requirement for
both ERK1/2 and p38 in osteoblast differentiation and bone
development.(18,22) Furthermore, both pathways were shown
to regulate osteoblast gene expression, at least in part, by
controlling the level of RUNX2 phosphorylation at specific serine
residues. However, the relative ability of ERK and p38 to
phosphorylate/activate RUNX2 and potential interactions
between these two kinases in osteoblasts had not previously
been examined. To address this issue, we developed a unique
antibody to monitor RUNX2 phosphorylation at serine 319, a site
phosphorylated by both ERK1/2 and p38a.(18,22) Under a variety
of conditions, a good correlation was observed between the level
of RUNX2 S319 phosphorylation measured on Western blots and
RUNX2 transcriptional activity measured using either a RUNX2-
specific reporter (6OSE2-luc) or a 1.3-kb murine osteocalcin gene
2 promoter–luciferase construct (1.3mOG2-luc). Despite the fact
that ERK1/2 and p38 can each phosphorylate RUNX2 at other
sites, the level of S319 phosphorylation appears to be a good
indicator of RUNX2 transcriptional activity (Figs. 5–7). For this
reason, this antibody should be a useful reagent for monitoring
RUNX2 activation under different physiological conditions.
Although ERK1/2, p38a and p38b can each phosphorylate and
activate RUNX2, large differences were noted when kinases were
compared. When assayed under conditions where each MAPK
was optimally stimulated by its respective MAPKK (constitutively
active MEK1 or MKK6), ERK1 was found to be four times
more active than p38b and nine times more active than
p38a in stimulating RUNX2-dependent transcription (Fig. 3).
As expected, differences in transcriptional activation were
paralleled by differences in the magnitude of RUNX2-S319
phosphorylation. The observation that ERK1/2 and p38 can both
phosphorylate RUNX2 at the same site is consistent with findings
in other systems. For example, T581 of MSK1 is phosphorylated
by ERK and p38 in response to oxidative stress,(36,37) while
both kinases phosphorylate the EGF receptor at T669, S1046,
and S1047.(38)
Phosphorylation/activation by either class of MAPKs required a
consensus MAPK docking D site in RUNX2 at residues 200–215
(RGKSTLTITVFTNPP; consensus sequence Rxxxxuxu where u is
L/I/V).(39) There are several examples of other transcription
factors with D sites that bindmore than oneMAPK. These include
Fig. 7. Comparison of ERK1/2 and p38 signaling in extracellular matrix
and BMP-induced osteoblast differentiation. (A,B) ECM-induced RUNX2
phosphorylation and differentiation is selectively associated with ERK1/2
activation. MC-42 cell were grown 50mg/mL AA for the indicated times.
Cells were harvested for measurement of luciferase (A) and Western blot
measurement of RUNX2, ERK, and p38 phosphorylation (B). (C,D) Role of
ERK1/2 and p38 signaling in ECM/BMP-induced differentiation. (C) Dose-
dependent induction of osteoblast gene expression by BMP2/7. MC-42
cell were grown for 7 days 50mg AA and the indicated concentrations
of BMP2/7 heterodimer and assayed for mOG2-luc activity. (D) Differen-
tial effects of ERK1/2 and p38 MAPK inhibitors on ECM and BMP-induced
RUNX2 phosphorylation and gene expression. MC-42 cell were grown for
7 days in the presence or absence of AA and/or saturating BMP2/7
(50mg/mL) and treated with U0126 and/or SB203580 16 hours before
harvest as indicated. Cells were assayed for mOG2-luc activity (upper
panel) or RUNX2, ERK, p38, and Smad1,5,8 phosphorylation (lower panel).
Statistically significant differences are indicated: Mp< 0.05, MMp< 0.01.
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Elk-1 (ERK and JNK), ATF-2 (p38 and JNK), and SAP-1/SAP-2 (ERK
and p38).(31) The D site in RUNX2 has properties similar to those
of other MAPK-responsive transcription factors in that it is
immediately N-terminal to a transcription activation domain that
contains MAPK phosphoacceptor sites necessary for transcrip-
tional activation(31) (ERK sites at S301, S319, S510(18) and p38 sites
at S254, S319).(22) Interestingly, ERK and p38 were shown to
compete for binding to the RUNX2 D site (Fig. 4). This
competition was demonstrated in two ways: (1) in coimmuno-
precipitation experiments, increasing levels of P-ERKwere able to
disrupt RUNX2:P-p38 complexes and vice versa. (2) Expression of
increasing amounts of DN ERK1 strongly inhibited ERK and p38-
dependent RUNX2-S319 phosphorylation and transcriptional
activity while DN p38b strongly inhibited p38 and partially
inhibited ERK1. Results from both these studies support the
conclusion that ERK1 has a relatively higher affinity for the D site
when compared with p38. One consequence of this competition
is that when constitutively active MKK6/p38b was expressed
in the presence of MEK1/ERK1, RUNX2 phosphorylation and
transcriptional activity was actually lower than that observed
with constitutively active MEK1/ERK1 alone, a result likely
because of displacement of ERK by the less active p38 (Fig. 3C).
Also, overexpression of DN MKK6, which blocked p38 activation,
actually increased P-ERK, RUNX2-S-319-P, and transcriptional
activity, again consistent with the idea that endogenous p38 was
initially competing with ERK on RUNX2 (Fig. 4F).
An additional important finding concerns the relationship
between ERK and p38 activities. Regardless of the experimental
system, we consistently found that suppression of oneMAPKwas
associated with activation of the other. This was true regardless
of whether we used pharmacological inhibitors to block ERK
versus p38 signaling (Fig. 5) or transgenic modification of MEK1
activity (Fig. 6) and was found in transfected COS7 cells, MC3T3-
E1 preosteoblasts, calvarial organ cultures, or primary osteoblasts
from transgenic mice. This reciprocal regulation had some
unexpected consequences. Although the ERK1/2 inhibitor,
U0126, consistently blocked RUNX2 phosphorylation, transcrip-
tional activity and calvarial mineralization (Fig. 5), p38 inhibition
with SB203580 either had no effect or actually increased RUNX2
phosphorylation and transcriptional activity. Because p38
stimulated RUNX2 activity in the overexpression studies shown
in Figures 2–4, one would have predicted its inhibition to reduce
activity. This paradoxical result may be a consequence of the
stimulation in ERK/MAPK activity found after SB203580 treat-
ment combined with a reduction of p38 at the RUNX2 D site
thereby allowing increased docking and phosphorylation by
ERK1/2. On the other hand, when cells/organ cultures were
treated with both ERK and p38 inhibitors, RUNX2 phosphoryla-
tion, transcriptional activity and mineralization (organ cultures
only) were reduced to levels below those observed with the ERK
inhibitor alone. This suggests that p38 is responsible for the
residual RUNX2 activity found in U0126-treated samples, but
does not have a major role in controlling RUNX2 activity under
conditions where there is a strong ERK/MAPK signal. Reciprocal
regulation of ERK and p38 MAPKs was previously reported in
other systems such as osteoclasts where inhibition of one MAPK
increases the other(40) and in osteoblasts from subchondral bone
that exhibit increased ERK and reduced p38 activity.(41)
Although in vivo transgenic studies clearly showed that ERK
and p38 MAPK pathways are both necessary for bone
formation,(20–22) based on our studies, it is unlikely that these
two kinases function in a redundant manner to control RUNX2
activity and osteoblast differentiation. Some insight into their
separate functions may be gleaned from the studies shown in
Figure 7 that compared AA and BMP-induced osteoblast
activities. Standard conditions for inducing osteoblast differenti-
ation involve providing an environment conducive to collagen
matrix secretion by inclusion of AA in tissue culture media.
Numerous studies showed that the resulting ECM induces
osteoblast differentiation, at least in part, by interacting with cells
via collagen-binding integrins (a2b1 and a1b1) and the
discoidin domain receptor 2 (DDR2), leading to activation of
ERK/MAPK signaling.(13,33) Although AA may also regulate gene
expression via activation antioxidant-responsive elements in
target genes,(42) its long-term effects on osteoblast differentia-
tion are most likely mediated by the ECM/integrin/MAPK
pathway described above. The ability of AA to dramatically
stimulate ERK/RUNX2 phosphorylation and osteoblast gene
expression was shown in Figure 7B. Under these conditions, P-
p38 levels remained essentially unchanged. AA-induced RUNX2
S319 phosphorylation and gene expression were highly sensitive
to the ERK/MAPK inhibitor, but were refractory to p38 inhibition
(Figs. 5, 7D). A different situation was encountered when the
combined effects of AA and BMP treatment were examined.
As previously reported,(14,43) induction of osteoblast gene
expression/differentiation by BMPs is synergistically stimulated
by AA (Fig. 7CD). The mild stimulation of gene expression by
BMPs in the absence of AA was sensitive to ERK, but not p38
inhibition. In contrast, in the presence of AA, BMP dramatically
stimulated P-ERK and RUNX2-S319 phosphorylation while
synergistically stimulating mOG2-luc activity. This response
was still completely blocked by ERK inhibition and partially
reduced with the p38 inhibitor. However, although ERK
inhibition completely blocked RUNX2 phosphorylation, p38
inhibition was without effect.
Several important conclusions may be drawn from these
studies: first, the BMP pathway can stimulate RUNX2 S319
phosphorylation and transcriptional activity, particularly in the
presence of AA, and this stimulation is not associated with
increased levels of RUNX2. This provides an alternate route for
BMP regulation of RUNX2 in addition to the previously described
induction of Runx2 expression.(44) Second, although BMPs via
TAK1 are known to activate all 3 MAPKs, ERK1/2 is a major
mediator of this response in osteoblasts with p38 having a minor
role via a mechanism unrelated to RUNX2 S319 phosphorylation.
Finally, the synergistic stimulation in gene expression observed
with BMP and AA treatment was also partly dependent on p38.
This p38 component distinguishes the AA/BMP response from
the response in cells treated only with AA that were resistant
to p38 inhibition. However, blocking p38 in this case did not
noticeably affect RUNX2-S319-P. This suggests either that
additional RUNX2 phosphorylation sites are involved or
that p38 regulates osteoblast gene expression by controlling
the activity of other transcription factors. In this regard, p38 is
known to phosphorylate/activate OSX or DLX5 in response to
BMP treatment.(45,46)
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